KR20080031676A - 신규한 옥사디아졸 유도체 및 대사성 글루타메이트수용체의 양성 알로스테릭 조절자로서의 그것의 용도 - Google Patents

신규한 옥사디아졸 유도체 및 대사성 글루타메이트수용체의 양성 알로스테릭 조절자로서의 그것의 용도 Download PDF

Info

Publication number
KR20080031676A
KR20080031676A KR1020077029357A KR20077029357A KR20080031676A KR 20080031676 A KR20080031676 A KR 20080031676A KR 1020077029357 A KR1020077029357 A KR 1020077029357A KR 20077029357 A KR20077029357 A KR 20077029357A KR 20080031676 A KR20080031676 A KR 20080031676A
Authority
KR
South Korea
Prior art keywords
phenyl
fluoro
oxadiazol
methanone
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077029357A
Other languages
English (en)
Korean (ko)
Inventor
피에르기울리아노 부가다
스테파니아 가글리아디
임마누엘 르 폴
뱅상 뮈텔
지오반니 팔롬비
장-필리프 로세
Original Assignee
아덱스 파마 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아덱스 파마 에스에이 filed Critical 아덱스 파마 에스에이
Publication of KR20080031676A publication Critical patent/KR20080031676A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020077029357A 2005-05-18 2006-05-17 신규한 옥사디아졸 유도체 및 대사성 글루타메이트수용체의 양성 알로스테릭 조절자로서의 그것의 용도 Ceased KR20080031676A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0510142.3 2005-05-18
GBGB0510142.3A GB0510142D0 (en) 2005-05-18 2005-05-18 Novel compounds A1

Publications (1)

Publication Number Publication Date
KR20080031676A true KR20080031676A (ko) 2008-04-10

Family

ID=34708380

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077029357A Ceased KR20080031676A (ko) 2005-05-18 2006-05-17 신규한 옥사디아졸 유도체 및 대사성 글루타메이트수용체의 양성 알로스테릭 조절자로서의 그것의 용도

Country Status (17)

Country Link
US (1) US20090197897A1 (cg-RX-API-DMAC10.html)
EP (1) EP1896463A2 (cg-RX-API-DMAC10.html)
JP (1) JP2008540634A (cg-RX-API-DMAC10.html)
KR (1) KR20080031676A (cg-RX-API-DMAC10.html)
CN (1) CN101218232B (cg-RX-API-DMAC10.html)
AU (1) AU2006248649B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0610681A2 (cg-RX-API-DMAC10.html)
CA (1) CA2608012A1 (cg-RX-API-DMAC10.html)
EA (1) EA015263B1 (cg-RX-API-DMAC10.html)
GB (1) GB0510142D0 (cg-RX-API-DMAC10.html)
IL (1) IL187190A0 (cg-RX-API-DMAC10.html)
MX (1) MX2007014405A (cg-RX-API-DMAC10.html)
NO (1) NO20076479L (cg-RX-API-DMAC10.html)
NZ (1) NZ564253A (cg-RX-API-DMAC10.html)
UA (1) UA92496C2 (cg-RX-API-DMAC10.html)
WO (1) WO2006123249A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200710277B (cg-RX-API-DMAC10.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006123255A2 (en) * 2005-05-18 2006-11-23 Addex Pharma Sa Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
GB0510140D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-842之用途
US20100144756A1 (en) 2007-07-13 2010-06-10 Bolea Christelle Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
WO2009099177A1 (ja) * 2008-02-06 2009-08-13 Taisho Pharmaceutical Co., Ltd. アミノイミダゾール誘導体
SA109300358B1 (ar) 2008-06-06 2012-11-03 استرازينيكا ايه بي مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
WO2010124055A1 (en) * 2009-04-23 2010-10-28 Merck Sharp & Dohme Corp. 2-alkyl piperidine mglur5 receptor modulators
CA2784830C (en) 2009-12-18 2018-03-27 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
ES2610362T3 (es) 2011-01-25 2017-04-27 Viviabiotech, S.L. Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido glp-1
DK2855453T3 (en) 2012-06-04 2017-02-06 Actelion Pharmaceuticals Ltd Benzimidazol-proline derivatives
BR112015007516A2 (pt) 2012-10-10 2017-07-04 Actelion Pharmaceuticals Ltd antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona
CN105051040A (zh) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
EP3275440B1 (en) * 2015-03-25 2022-05-04 National Center for Geriatrics and Gerontology Novel oxadiazole derivative and pharmaceutical containing same
US12590083B2 (en) 2019-01-25 2026-03-31 University Of Virginia Patent Foundation Inhibitors of spinster homolog 2 (SPNS2) for use in therapy
WO2022056042A1 (en) * 2020-09-09 2022-03-17 University Of Virginia Patent Foundation Inhibitors of spinster homolog 2 (spns2) for use in therapy
IL291418B2 (en) 2022-03-16 2024-05-01 Anima Biotech Inc Substances that function as modulators of cMYC-mRNA translation and their uses for cancer treatment
CN117756793A (zh) * 2022-12-16 2024-03-26 四川大学 1,2,4-杂二唑衍生物及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK162087D0 (da) * 1987-03-31 1987-03-31 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
US6107313A (en) * 1998-10-02 2000-08-22 Combichem, Inc. Dopamine receptor antagonists
US6440996B1 (en) * 1998-10-07 2002-08-27 Georgetown University Monomeric and dimeric heterocycles, and therapeutic uses thereof
AU5891600A (en) * 1999-07-01 2001-01-22 Chemrx Advanced Technologies, Inc. Process for synthesizing oxadiazoles
ATE307129T1 (de) * 1999-08-19 2005-11-15 Nps Pharma Inc Heteropolycyclische verbindungen und ihre verwendung als antagonisten von metabotropen glutamatrezeptoren
AU2001233044A1 (en) * 2000-01-28 2001-08-07 Akkadix Corporation Methods for killing nematodes and nematode eggs using bis-amino-1,2,4-thiadiazoles
PL369598A1 (en) * 2001-02-21 2005-05-02 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
IL160701A0 (en) * 2001-09-21 2004-08-31 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives
EP1427720B1 (en) * 2001-09-21 2009-03-04 Mitsubishi Tanabe Pharma Corporation 3-substituted-4-pyrimidone derivatives
US6995144B2 (en) * 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
AU2003264018A1 (en) * 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
WO2004014881A2 (en) * 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
JP2006503827A (ja) 2002-09-06 2006-02-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アレルギー性鼻炎治療用薬剤を製造する目的でインドリル誘導体を用いる使用
PL1633724T3 (pl) * 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
AU2004226450A1 (en) 2003-03-26 2004-10-14 Merck & Co. Inc. Benzamide modulators of metabotropic glutamate receptors
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
SG149900A1 (en) * 2004-02-18 2009-02-27 Astrazeneca Ab Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
BRPI0515851A (pt) * 2004-09-29 2008-08-12 Mitsubishi Pharma Corp composto de pirimidona
GB0510143D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
WO2006123255A2 (en) * 2005-05-18 2006-11-23 Addex Pharma Sa Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0510140D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds

Also Published As

Publication number Publication date
EA200702468A1 (ru) 2008-06-30
ZA200710277B (en) 2009-03-25
IL187190A0 (en) 2008-02-09
EP1896463A2 (en) 2008-03-12
NZ564253A (en) 2011-04-29
CN101218232B (zh) 2012-06-27
MX2007014405A (es) 2008-04-21
AU2006248649B2 (en) 2012-04-26
UA92496C2 (ru) 2010-11-10
US20090197897A1 (en) 2009-08-06
BRPI0610681A2 (pt) 2010-07-20
WO2006123249A3 (en) 2007-02-08
CA2608012A1 (en) 2006-11-23
CN101218232A (zh) 2008-07-09
GB0510142D0 (en) 2005-06-22
AU2006248649A1 (en) 2006-11-23
JP2008540634A (ja) 2008-11-20
WO2006123249A2 (en) 2006-11-23
NO20076479L (no) 2008-01-29
EA015263B1 (ru) 2011-06-30

Similar Documents

Publication Publication Date Title
AU2006248649B2 (en) Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
EP1912979B1 (en) Phenyl-{3-(3-(1h-pyrrol-2-yl)-[1,2,4]oxadiazol-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors
US20100004284A1 (en) Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors
US20100081690A1 (en) Oxazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
WO2006048771A1 (en) Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
KR20080027463A (ko) 대사성 글루타메이트 수용체의 양성 알로스테릭조절자로서의 치환된 옥사디아졸 유도체
CN101228155B (zh) 作为代谢型谷氨酸受体的正变构调节剂的取代的*二唑衍生物
HK1112909B (en) Phenyl-{3-(3-(1h-pyrrol-2-yl)-[1,2,4]oxadiazol-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20071214

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110513

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130325

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130826

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130325

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I